Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: Kimberly Schluns Clear advanced filters

  • Interleukin-2 receptor-α (IL-2Rα) on antigen-presenting dendritic cells (DCs) is now shown to trans-present IL-2 to T cells during the earliest stages of T cell activation (604–609). The resulting T cell proliferation is blocked by daclizumab, an IL-2Rα–specific antibody used to treat multiple sclerosis and prevent transplant rejection, highlighting the importance of understanding individual variability in immune responses to daclizumab treatment.

    • Kimberly S Schluns
    News & Views
    Nature Medicine
    Volume: 17, P: 545-547

  • Interleukin (IL)-17 expressing helper T cells (TH17) have recently been identified as a effector subset involved in tissue inflammation. In this paper, it is shown that the cytokine IL-21 is induced downstream of IL-6 by a STAT3 dependent mechanism and participates in inducing TH17 cell differentiation in an autocrine and ROR-γ dependent manner

    • Roza Nurieva
    • Xuexian O. Yang
    • Chen Dong
    Research
    Nature
    Volume: 448, P: 480-483

  • Cancer vaccines have had limited success in eliminating tumors in patients. Here Willem Overwijk and colleagues report that one reason for the failure of peptide-based vaccines may be their formulation. Their research shows that peptides formulated in incomplete Freund's adjuvant sequester CD8+ T cells at the site of injection, leading to T cell dysfunction and eventual apoptosis. A peptide and adjuvant formulation that did not persist long term at the injection site showed superior ability to induce a functional antitumor T cell response.

    • Yared Hailemichael
    • Zhimin Dai
    • Willem W Overwijk
    Research
    Nature Medicine
    Volume: 19, P: 465-472

  • Grail is an E3 ubiquitin ligase that inhibits T-cell receptor signalling in CD4+ T cells. Here the authors show Grail also limits IL-21 receptor expression and function in CD8+ T cells, is overactive in these cells in patients with lymphoma, and promotes tumour development in a lymphoma transplant mouse model.

    • Cara Haymaker
    • Yi Yang
    • Roza Nurieva
    ResearchOpen Access
    Nature Communications
    Volume: 8, P: 1-14